Does Eliquis Protect Against Both Venous and Arterial Thrombosis?
Yes, Eliquis (apixaban) provides protection against both venous and arterial thromboembolism, but with different levels of evidence and FDA approval for each indication.
FDA-Approved Indications
Eliquis is FDA-approved for both venous and arterial thrombotic conditions 1:
Venous Thromboembolism (VTE)
- Treatment of acute DVT and PE: 10 mg twice daily for 7 days, then 5 mg twice daily
- Prevention of recurrent VTE: After initial treatment, can use either 5 mg or 2.5 mg twice daily
- VTE prophylaxis after orthopedic surgery: 2.5 mg twice daily following hip or knee replacement
Arterial Thromboembolism
- Stroke prevention in atrial fibrillation: 5 mg twice daily (or 2.5 mg twice daily if meeting dose-reduction criteria)
- This addresses arterial thromboembolism, as AF-related strokes are cardioembolic (arterial) events
Evidence Quality and Efficacy
For venous thrombosis, the AMPLIFY trial demonstrated non-inferiority to enoxaparin/warfarin for treating DVT/PE, with apixaban showing a 2.3% rate of recurrent VTE compared to 2.7% with warfarin 1. The AMPLIFY-EXT study confirmed efficacy for extended VTE prevention 1.
For arterial thrombosis in AF, apixaban is recommended as first-line therapy over warfarin by the 2024 ESC guidelines 2. Meta-analyses show DOACs including apixaban reduce stroke/systemic embolism (HR 0.81), all-cause mortality (HR 0.90), and intracranial bleeding (HR 0.48) compared to warfarin 2.
Critical Limitation: Acute Coronary Syndrome
Apixaban failed in arterial thrombosis prevention for acute coronary syndrome (ACS). When added to dual antiplatelet therapy (aspirin + clopidogrel) in ACS patients, apixaban at 5 mg twice daily resulted in unacceptably high bleeding rates without sufficient benefit, leading to early trial termination 3, 4, 5. This represents a major exception to its arterial protection profile.
Recent High-Quality Evidence
The 2026 COBRRA trial (most recent high-quality study) demonstrated apixaban's superiority over rivaroxaban for VTE treatment, with significantly lower clinically relevant bleeding (3.3% vs 7.1%, P<0.001) 6. This reinforces apixaban's strong venous thrombosis protection profile.
For extended VTE treatment in cancer patients, the 2025 API-CAT trial showed reduced-dose apixaban (2.5 mg twice daily) was noninferior to full-dose for preventing recurrent VTE while causing less bleeding 7.
Practical Algorithm for Dual Risk Patients
When patients have both venous and arterial thrombotic risk:
- Define the primary indication: Is anticoagulation needed for AF (arterial) or VTE (venous)?
- Assess bleeding risk: Use validated scores and patient-specific factors
- Determine if antiplatelet therapy is also needed:
- If patient has coronary stents or recent MI, dual therapy (anticoagulation + single antiplatelet) may be necessary
- Avoid triple therapy (anticoagulation + dual antiplatelet) beyond the acute period due to excessive bleeding risk 8
- Choose apixaban dosing based on the primary indication 1:
- AF: 5 mg twice daily (or 2.5 mg if meeting reduction criteria)
- Acute VTE: 10 mg twice daily × 7 days, then 5 mg twice daily
- Extended VTE prevention: Consider 2.5 mg twice daily after initial treatment
Important Caveats
- Not for mechanical heart valves or moderate-to-severe mitral stenosis 2, 1
- Not recommended for ACS as monotherapy or added to dual antiplatelet therapy 3, 4
- Peripheral artery disease: Limited data; management requires individualized assessment of arterial vs. bleeding risk 8
- Spinal/epidural procedures: Significant risk of spinal hematoma with neuraxial anesthesia 1
The ASH 2020 guidelines suggest standard-dose or reduced-dose apixaban may both be used for secondary VTE prevention, though this is a conditional recommendation based on moderate certainty evidence 9.